Preventive Effect of Two New Neurotensin Analogues on Parkinson’s Disease Rat Model
- 30 October 2018
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 66 (4) , 552-560
Abstract
Close functional and anatomical interactions between the neurotensin (NT) and dopamine (DA) systems suggest that NT could be associated with Parkinson’s Disease (PD). However, clinical use of NT is limited due to its rapid degradation. This has led to the synthesis of a number of new NT fragment 8-13 [NT(8-13)] analogues, such as NT2 and NT4, to avoid the fast biodegradation of NT. The aim of this study was to investigate the neuroprotective effects of NT2 and NT4 on an experimental model of Parkinson’s disease in rats induced with 6-hydroxydopamine (6-OHDA) treatment, producing striatal lesions. Wistar male rats were divided into different groups: a sham-operated (SO) group, a striatal 6-OHDA-lesioned control group, two groups of 6-OHDA-lesioned rats treated for 5 days with NT2 or NT4 (10 mg/kg, intraperitoneally) and a NT-treated group as reference. During the first and second week post lesion the animals were subjected to a number of behavioral tests (apomorphine-induced rotations, rotarod, passive avoidance test), and brain tissue was evaluated histologically and also assessed for DA levels. The results showed that both the number of apomorphine-induced rotations and falls (rotarod test) increased in the 6-OHDA group relative to the SO group. At the same time, the 6-OHDA-treated group showed significant memory impairment, based on the to step-through test, compared to the SO group. Treatment with NT2 and NT4 significantly decreased the number of apomorphine-induced rotations and improved the memory of lesioned animals, with these NT analogues demonstrating better neuroprotective and neuromodulatory effects than NT. DA content in the brain of the PD rats treated with NT2 and NT4 increased, possibly due to attenuation of the loss of DA-ergic neurons. NT2 and NT4 were found to easily penetrate the blood–brain barrier and they showed a better stability than the reference NT neuropeptide. In conclusion, the NT approach represents an attractive strategy for the treatment of neurodegenerative disease.Keywords
This publication has 45 references indexed in Scilit:
- Knocking Out DJ-1 Attenuates Astrocytes Neuroprotection Against 6-Hydroxydopamine ToxicityJournal of Molecular Neuroscience, 2013
- Neurotensin Modulates the Migratory and Inflammatory Response of Macrophages under Hyperglycemic ConditionsBioMed Research International, 2013
- Neurotensin receptors as modulators of glutamatergic transmissionBrain Research Reviews, 2008
- Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA modelJournal of Neuroscience Methods, 2006
- Novel pharmacological targets for the treatment of Parkinson's diseaseNature Reviews Drug Discovery, 2006
- Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neuronsJournal of Comparative Neurology, 2004
- Increased plasma neurotensin concentrations in patients with Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Effect of Acute -Dopa Pretreatment on Apomorphine-Induced Rotational Behavior in a Rat Model of Parkinson's DiseaseExperimental Neurology, 2000
- Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjectsBiochemical and Biophysical Research Communications, 1984
- Synthesis and Characterization of Neurotensin Analogues for Structure/Activity Relationship StudiesEuropean Journal of Biochemistry, 1982